Ablation zone delineation with MRI during thermal ablation of liver tumours

Ablation zone delineation with MRI during thermal ablation of liver tumours - DELIVER

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45796

Enrollment

Registered

2019-02-26

Start date

2019-10-16

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer liver tumors

Interventions

All patients will receive MRI-guided RFA/MWA treatment of liver tumours with per-procedural ablation zone imaging.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18 years and over. - Indication for liver RFA/MWA treatment assessed by the multidisciplinary liver tumor board. - Written (signed and dated) informed consent.

Exclusion criteria

Exclusion criteria: - Insufficient command of the Dutch language to be able to understand the patient information. - Pregnancy - Contraindications for MRI - Contraindications for liver RFA/MWA treatment

Design outcomes

Primary

Measure	Time frame
Primary outcome is the feasibility of real-time MRI temperature monitoring and ablation zone assessment during thermal ablation of hepatic malignancies.	—

Secondary

Measure	Time frame
Secondary outcomes are correlation of per-procedural MRI-guided delineated ablation zone with the ablation zone depicted on follow-up CT six weeks after treatment and the predicted ablation zone by manufacturer specifications, and the influence of patient and procedure characteristics on whether the predicted ablation zone is reached.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)